Bioventus' Surgical Growth and Strategic Review Rationale Clash in 2026 Q2 Earnings Call

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $153M, up 4% compared to the prior year period
• EPS: $0.22 per diluted share (adjusted), compared to $0.21 in the prior year period
• Gross Margin: 75% adjusted, 90 basis points lower than the prior year period
• Operating Margin: 23% adjusted EBITDA margin, expanded 20 basis points compared to the prior year

Guidance:

• Revenue for full year 2026 expected to be in the range of $600 million to $610 million.
• Adjusted EPS for full year 2026 expected to be between $0.75 to $0.79 per diluted share.
• Cash from operations for full year 2026 expected to range between $84 million and $89 million.
• Expect year-over-year revenue growth in second half to increase compared to first half by over 300 basis points.
• Expect cash from operations to approximately double in the second half compared to the first half.
• Expect net leverage to be below 1.5x by year-end.

Business Commentary:

Revenue and Earnings Growth:

• BioVentus, Inc. reported revenue of $153 million for Q2 2026, up 4% compared to the prior year period.
• The company's adjusted EBITDA was $35 million, also an increase of over $1 million year-over-year.
• Growth was driven by strong performance in the pain treatments business, particularly double-digit growth in the HA franchise, and increased investments in key growth drivers like PRP, PNS, and ultrasonics.

Cash Flow and Debt Reduction:

• Cash from operations for the quarter totaled $20 million, and the company repaid an additional $24 million of its term loan.
• This has reduced the company's net leverage to below 2x, with an expectation to be below 1.5x by year-end.
• The strong cash generation was due to robust profitability, disciplined working capital management, and a capital-light business model.

Strategic Investment and Future Outlook:

• The company is seeing positive traction in PRP with larger and more frequent disposable reorders and increased capital placements.
• In PNS, there has been increased velocity in surgeon adoption and a high conversion rate of trial placements to permanent implants.
• Investments in these areas are expected to translate into revenue acceleration in the second half of 2026 and beyond, supported by a strategic focus on expanding sales force coverage and clinical support.

International Growth and Market Positioning:

• International revenue was $19 million, slightly down by 1% year-over-year, primarily due to timing of distributor orders.
• The fundamental growth in international markets remains strong, with expectations for strong double-digit growth in the second half of the year.
• This is attributed to increased strategic focus, new talent additions, and improved commercial execution in select markets.

Strategic Review and Shareholder Value:

• Following receipt of multiple expressions of interest and an unsolicited acquisition proposal, BioVentus' board has formed a committee to evaluate strategic options.
• The evaluation includes a potential sale of the company or continued execution of its standalone plan.
• The company aims to maximize shareholder value by carefully considering all options, supported by its strong foundation for growth and success.

Sentiment Analysis:

Overall Tone: Positive

• Management highlighted 'positive momentum,' 'solid financial results,' and 'encouraging leading indicators.' They reiterated full-year guidance, stated they are 'confident in our future growth drivers,' and noted 'strong progress to date.' The company was recognized as a 'best company to work for,' and they expressed being 'excited about our significant progress and enormous potential ahead.'

Q&A:

• Question from Chase Knickerbocker (Craig Hallam): Can you give us an idea of volume versus price performance in the quarter for Duralane and characterize the competitive dynamics in the single injection market?
  Response: Growth was led by double-digit volume growth for Duralane, driven by clinical differentiation, private payer coverage, and commercial strengths, with no mention of competitive share loss.

• Question from Chase Knickerbocker (Craig Hallam): Can you discuss visibility into capital pushed into the second half, and break down growth by ultrasonics and BGS, including capital vs. handpiece growth?
  Response: Surgical solutions grew 5% sequentially despite a ~400 bps headwind from timing-shifted capital; ultrasonics showed strong traction in leading indicators, while BGS had a temporary impact from proactive portfolio actions but positive new account traction expected to drive second-half acceleration.

• Question from Chase Knickerbocker (Craig Hallam): Can you contextualize the strategic alternatives process?
  Response: The process was initiated following an unsolicited acquisition proposal and multiple expressions of interest; the board is evaluating options to maximize shareholder value, and management remains excited about the company's progress and potential.

• Question from Larry Solo (CJS Securities): Can you provide color on PRP and PNS customer reception and early progress?
  Response: For PRP: Encouraged by new customer velocity, accelerated capital placements, and increased reorder size; leveraging HA sales force synergistically. For PNS: Excited about team expansion, new customer and trial acceleration, and strong conversion rates to implants, targeting over $100M in growth.

• Question from Larry Solo (CJS Securities): Given sales grew 5% and EBITDA grew 12%, is margin expansion still expected for the year despite increased investments?
  Response: Confident in P&L control and peer-leading gross margins; full-year EBITDA margin expectation is at least 20%, with continued investment (exceeding $13M) primarily in P&S and PRP, expecting strong returns.

• Question from Caitlin Roberts (Canaccord Genuity): Can you provide more color on Exogen's change in customer mix and the CMS pricing reversal?
  Response: Exogen's decline was due to a shift in payer mix with fewer Medicare orders, but volume grew and low-to-mid-single-digit growth is expected in second half; the CMS pricing reversal is not a material change.

• Question from Caitlin Roberts (Canaccord Genuity): Are you planning data/evidence generation for P&S, and have surgeons focused on that?
  Response: Yes, evidence generation is part of the plan to augment clinical differentiation, though initial market reception is strong.

• Question from Michael Petusky (Barrington Research): Did you walk away from any business in the quarter, and can you quantify it?
  Response: For BGS, proactive actions were taken for temporary impact, but positive traction with new accounts and early penetration provides line of sight to second-half acceleration; no details on quantification provided.

• Question from Michael Petusky (Barrington Research): Has the P&S asset been a significant factor in the strategic review?
  Response: P&S is an exciting part of the portfolio, but overall the company has strength, momentum, and potential, attracting attention; management is focused on maximizing shareholder value through the evaluation process.

Contradiction Point 1

Surgical Business Performance and Growth Expectations

Contradiction in reported sequential growth and capital placement impact for the Surgical business.

Chase Knickerbocker (Craig Hallam) - Chase Knickerbocker (Craig Hallam)

2026Q2: The surgical business grew 5% sequentially in Q2 despite a ~400 basis point impact from timing shifts in capital placements. - Rob Claypool(CEO)

Can you discuss visibility into capital allocation for the second half, break down growth for ultrasonics and BGS, and compare capital versus handpiece growth in ultrasonics? - Chase Knickerbocker (Craig-Hallum)

2026Q2: Despite a difficult comparison and a ~$2M (~400 bps) timing shift in Ultrasonics capital from Q2 to H2, Surgical Solutions grew 5% sequentially. - Rob Claypoole(CEO)

Contradiction Point 2

Strategic Alternatives Process Rationale

Contradiction in the stated primary driver for initiating the strategic review process.

Chase Knickerbocker (Craig Hallam) - Chase Knickerbocker (Craig Hallam)

2026Q2: The strategic review was prompted by an unsolicited acquisition proposal and other expressions of interest. - Rob Claypool(CEO)

What is the current status of the strategic alternatives process? - Michael Petusky (Barrington Research)

2026Q2: The entire company’s strength, momentum, and potential—highlighted by 5% revenue growth, 12% EBITDA, 24% EPS growth, and $46M debt paydown—have attracted attention. PNS is an exciting part of the portfolio in a high-valuation market, contributing to the review. - Rob Claypoole(CEO)

Contradiction Point 3

Impact of Rebates on Financial Guidance

Inconsistent rationale for not raising full-year revenue guidance despite positive developments.

Chase Knickerbocker (Craig Hallam) - Chase Knickerbocker (Craig Hallam)

2026Q2: The favorable rebate was a one-time process change by a payer partner... Revenue guidance was not raised because the first quarter is only a quarter into the year... - Robert Claypoole(CEO)

Can you provide insights on Duralane's volume versus price performance in the quarter and the competitive dynamics in the single injection market? - Lawrence Solow (CJS Securities, Inc.)

2026Q2: The first half performance was led by double-digit volume growth for Duralane. Growth is driven by clinical differentiation, broad private payer coverage, and commercial strengths. The company expects continued growth in the back half of the year, primarily through volume increases. - Rob Claypool(CEO)

Contradiction Point 4

Growth Drivers and Business Acceleration

Contradiction on the primary drivers and timing of business acceleration.

Chase Knickerbocker (Craig Hallam) - Chase Knickerbocker (Craig Hallam)

2026Q2: The company expects continued growth in the back half of the year, primarily through volume increases. - Rob Claypool(CEO)

How did Duralane's volume versus price performance in the quarter reflect the competitive dynamics in the single injection market? - Chase Knickerbocker (Craig-Hallum Capital Group)

2025Q4: The strategy prioritizes accretive, long-term profitable growth to fund future growth drivers (PNS, PRP), not market growth rates. - Robert Claypoole(CEO)

Contradiction Point 5

Strategic Alternatives Process Context

Contradiction on the catalyst and focus of the strategic review process.

Chase Knickerbocker (Craig Hallam) - Chase Knickerbocker (Craig Hallam)

2026Q2: The process was initiated following an unsolicited acquisition proposal and multiple expressions of interest. - Rob Claypool(CEO)

Can you update us on the current status of the strategic alternatives process? - (Questioner's Name not provided in the summary)

2025Q4: The company is focused on maximizing shareholder value through the evaluation of all options. - Rob Claypool(CEO)